amacin eye & ear ointment
jurox pty limited - neomycin sulfate; polymyxin b sulfate; sulfacetamide sodium; prednisolone - misc. aural, ophthalmic, oro/naso pharyngeal - neomycin sulfate antibiotic active 5.0 mg/g; polymyxin b sulfate antibiotic active 5000.0 iu/g; sulfacetamide sodium sulfanyl active 50.0 mg/g; prednisolone steroid-glucocorticoid active 2.5 mg/g - ear,nose,throat + ocular - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - ear infections | infection - ocular | eye infections | ocular infections
neomycin and polymyxin b sulfates and gramicidin- neomycin sulfate, polymyxin b sulfate and gramicidin solution/ drops
physicians total care, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), gramicidin (unii: 5ie62321p4) (gramicidin - unii:5ie62321p4) - neomycin sulfate 1.75 mg in 1 ml - neomycin and polymyxin b sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. this product is contraindicated in those persons who have shown hypersensitivity to any of its components.
neomycin and polymyxin b sulfates and gramicidin- neomycin sulfate, polymyxin b sulfate and gramicidin solution/ drops
rebel distributors corp - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), gramicidin (unii: 5ie62321p4) (gramicidin - unii:5ie62321p4) - neomycin sulfate 1.75 mg in 1 ml - neomycin and polymyxin b sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. this product is contraindicated in those persons who have shown hypersensitivity to any of its components.
neomycin sulfate tablet
hi-tech pharmacal co. inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidimiology and susceptibility patterns may contribute to the empiric selection of therapy. suppression of intestinal bacteria : neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, eg, preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration section) . hepatic coma (portal-systemic encephalopathy) : neomycin sulfate has been shown to be effective adjunctive therapy in hepatic com
neomycin sulfate tablet
xgen pharmaceuticals djb, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets, usp and other antibacterial drugs, neomycin sulfate tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. neomycin sulfate tablets, usp are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g. preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration section) . neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal
neomycin polymyxin b sulfates and dexamethasone- neomycin sulfate, polymyxin b sulfate and dexamethasone suspension/ drops
mwi/vetone - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin sulfate 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterobacter sp
neomycin polymyxin b sulfates and dexamethasone- neomycin sulfate, polymyxin b sulfate and dexamethasone suspension/ drops
phoenix pharmaceutical, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin sulfate 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterobacter sp
neomycin sulfate, polymyxin b sulfate and dexamethasone- neomycin, polymyxin b and dexamethasone suspension
stat rx llc usa - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin sulfate 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae,
neomycin and polymyxin b sulfates and gramicidin- neomycin sulfate, polymyxin b sulfate and gramicidin solution/ drops
bausch & lomb incorporated - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), gramicidin (unii: 5ie62321p4) (gramicidin - unii:5ie62321p4) - neomycin 1.75 mg in 1 ml - neomycin and polymyxin b sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. this product is contraindicated in those persons who have shown hypersensitivity to any of its components.
neomycin and polymyxin b sulfates and gramicidin- neomycin sulfate, polymyxin b sulfate and gramicidin solution/ drops
dispensing solutions, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), gramicidin (unii: 5ie62321p4) (gramicidin - unii:5ie62321p4) - neomycin 1.75 mg in 1 ml - neomycin and polymyxin b sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. this product is contraindicated in those persons who have shown hypersensitivity to any of its components.